Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.81 |
| ▸ | MMP9 | P14780 | 13/20 | 0.81 |
| ▸ | ADAM17 | P78536 | 12/20 | 0.81 |
| ▸ | MMP1 | P03956 | 10/20 | 0.81 |
| ▸ | MMP3 | P08254 | 5/20 | 0.81 |
| ▸ | MMP7 | P09237 | 4/20 | 0.81 |
| ▸ | MMP8 | P22894 | 4/20 | 0.81 |
| ▸ | MMP13 | P45452 | 4/20 | 0.81 |
| ▸ | MMP14 | P50281 | 4/20 | 0.81 |
| ▸ | MMP15 | P51511 | 1/20 | 0.81 |
| ▸ | MMP16 | P51512 | 1/20 | 0.81 |
| ▸ | ADAM33 | Q9BZ11 | 1/20 | 0.81 |
| ▸ | ADAM10 | O14672 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196761 | 0.91 | ADAM17 (0.84) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6692506 | 0.90 | ADAM17 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL10052499 | 0.90 | ADAM17 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL5966106 | 0.90 | ADAM17 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL2834283 | 0.90 | ADAM17 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL4197086 | 0.87 | MMP2 (0.78) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6627417 | 0.85 | ADAM17 (1.00) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL4210099 | 0.84 | ADAM17 (0.73) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL4214029 | 0.83 | MMP2 (0.77) | MMP2MMP9ADAM17MMP1MMP3 | |
| SCHEMBL6627454 | 0.83 | ADAM17 (0.78) | MMP2MMP9ADAM17MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090192191-A1 | Substituted hydroxamic acid derivatives as tnf inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2009-07-30 | — | — | US | claimed |
| WO-2005077937-A1 | SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS TNF INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | claimed |
| US-20090192191-A1 | Substituted hydroxamic acid derivatives as tnf inhibitors | CADILA HEALTHCARE LIMITED (IN) | 2009-07-30 | — | — | US | disclosed |
| WO-2005077937-A1 | SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS TNF INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192191-A1 | Substituted hydroxamic acid derivatives as tnf inhibitors | TNF, TNFRSF1A, TIMP3 | MMP2 4/4885MMP9 6/4885ADAM17 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.